KIT and acute myeloid leukemia: Functional studies have highlighted ezrin as a key mediator in signaling pathways driven by FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) and mutated c-kit (KIT) receptors, promoting the survival of AML cells [78–80].